VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings validating its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. The announcement marks a significant step forward for the company’s innovative approach to antibody-drug conjugates (ADCs), which are designed to deliver potent anti-cancer agents directly to tumors while minimizing harm to healthy tissues.
The in vivo study demonstrated significant tumor regression in a breast cancer model following a single 3 mg/kg dose, with no observed decrease in body weight. This suggests that the treatment was well-tolerated and effective in reducing tumor size. Critically, the results also showed that both BiTAC-ADC components were required to produce the intended tumor-specific response, highlighting the platform’s dual-targeting mechanism that may enhance precision and reduce off-target effects.
Additional in vitro studies demonstrated the platform’s ability to distinguish cancer cells from healthy cells, prevent the release of active toxins outside the tumor, and target multiple cancer cell lines. These findings support the potential of BiTAC-ADCs to deliver efficacy comparable to conventional antibody-drug conjugates while offering a differentiated safety profile designed to reduce systemic toxicity. For patients, this could mean more effective treatments with fewer side effects, addressing a major challenge in cancer therapy.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.
The news is important for the biotech industry as it validates a novel platform that could overcome limitations of existing ADCs, such as narrow therapeutic windows and systemic toxicity. If successful in clinical trials, BiTAC-ADCs could become a new standard of care for various cancers, potentially improving patient outcomes and expanding treatment options. For investors, this data represents a key milestone that de-risks the platform and could accelerate partnerships or funding. The full press release can be viewed at https://ibn.fm/cs8SW. The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA.
BillionDollarClub, a specialized communications platform, highlighted the announcement. As one of 70+ brands within the Dynamic Brand Portfolio @ IBN, BDC delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. This broad reach ensures that important developments like VERAXA’s are disseminated to a wide audience of investors and industry stakeholders.
